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Estrogens have preventative effects on weight gain and associated comorbidities, but the tissue-specific
targets remain unknown. Here, Xu et al. (2011) demonstrate that ablation of estrogen signaling in two popu-
lations of hypothalamic neurons leads to weight gain and subsequent metabolic dysregulation and could be
important target sites of estrogen actions.The obesity epidemic continues to pose
one of the largest worldwide threats to
overall health, and currently there are
few effective preventative or therapeutic
options. Determining the factors that
mediate both weight gain and its meta-
bolic effects is a priority, as this under-
standing may both allow for stratification
of populations at risk and the discovery
of pharmacologic targets for eventual
therapies. Estrogen receptors are one
such potential target, as estrogen signal-
ing has been shown to have powerful
metabolic effects in both clinical and
experimental models. Selective estrogen
receptor modulators (SERMs) may be of
benefit, having the ability to activate estro-
gen receptors in specific tissues while
remaining inert or leading to inactivation
in others. In this issue of Cell Metabolism,
Xu et al. (2011) identify key targets within
the central nervous system, as shown in
Figure 1, which may represent an impor-
tant step toward developing SERMs de-
signed to counter the obesity crisis.
In humans, population-based studies of
postmenopausal women have shown that
the risks of insulin resistance, fatty liver
disease, and cardiovascular disease are
increased compared to age-matched
controls (Carr, 2003). Body composition
changes, specifically a redistribution of
fat toward the visceral compartment,
parallel these risks. Estrogen replacement
therapy (HRT) has a protective effect
against many of these changes. However,
the increased cardiovascular and cancer
risks associated with HRT make estrogen
replacement itself an unsuitable option
for preventative use (Rossouw et al.,
2002), hence the need for more targeted
therapies.
Despite this growing need, currently
little is known regarding the specific sitesof action necessary for estrogen to exert
its protective effects or its cellular mecha-
nism of action. The impact on obesity has
been shown to be mediated primarily by
signaling through estrogen receptor-a
(ERa). Nearly two decades ago, we
described a male patient with an ERa
loss-of-function mutation (Smith et al.,
1994). By age 24, this patient had overt
type 2 diabetes and hyperinsulinemia
with a BMI in the obese range. Animal
studies later corroborated these findings,
demonstrating that global knockout of
ERa is sufficient to produce excess
weight gain, increased visceral fat, glu-
cose intolerance, insulin resistance, and
dyslipidemia (Ribas et al., 2010).However,
as ERa is expressed in a number of tis-
sues, including muscle, liver, adipocytes,
reproductive organs, and the central ner-
vous system, this discovery did not iden-
tify the precise site of action for estrogen
and ERa signaling.
The study by Xu et al. represents an
important step in the narrowing of this
vast array of possibilities. By using a
Nestin-Cre construct to greatly reduce
ERa expression within the entire central
nervous system, Xu et al. were able to
demonstrate abnormal weight gain in
both male and female mice with associ-
ated glucose intolerance. The females
also had increased body fat and visceral
fat compared to wild-type controls. Inter-
estingly, both hyperphagia and reduced
energy expenditure were observed in
these conditional knockouts. While each
could certainly contribute to the increased
weight gain, this observation differs from
previous studies examining metabolic
parameters in whole-body ERa knock-
outs (Park et al., 2011; Ribas et al., 2010)
that showed decreased energy consump-
tion without increased food intake. OneCell Metabolism 1potential explanation for this discrepancy
is that high levels of circulating estradiol
were seen in the Nestin-Cre conditional
knockouts while peripheral ERa signaling
remained largely intact, a major difference
in these models.
To further delineate the regions of the
CNS involved, Xu et al. focused on the
importanceofERa signaling in twopopula-
tions of hypothalamic neurons known to
be involved in regulating metabolism and
energy balance.Within the brain, steroido-
genic factor-1 (SF1) is expressed exclu-
sively in neurons of the ventromedial
hypothalamus. Signaling in SF1 neurons is
essential for the compensatory increase
in energy expenditure seen after exposure
to a hypercaloric diet (Xu et al., 2010). By
suppressing ERa expression specifically
in SF1-expressing cells, Xu et al. demon-
strated an important role for estrogen
signaling in the impact of these neurons
on energy homeostasis and body fat
partitioning, particularly in females. The
latter of these effects is particularly in-
triguing in that adipocyte size and tri-
glyceride content were elevated only in
gonadal (visceral) adipose tissue, the com-
partment most associated with impaired
glucose tolerance and dyslipidemia. Fur-
ther work to elucidate how these central
signals modulate the observed peripheral
effects is an important next step.
The second population of neurons in-
vestigated were neurons in the arcuate
nucleus of the hypothalamus expressing
pro-opiomelanocortin (POMC). POMC
neurons are important for regulation of
food intake through the secretion of a-
melanocyte-stimulating hormone, which
signals through the melanocortin-4 re-
ceptor (MC4R) to induce satiety. In hu-
mans, MC4R mutations are the most
common genetic cause of nonsyndromic4, October 5, 2011 ª2011 Elsevier Inc. 435
Figure 1. Effects of Hypothalamic Estrogen Signaling on Body
Weight
A schematic illustrating three outcomes of estrogen signaling mediated
through ERa via two populations of hypothalamic neurons as demonstrated
in the study by Xu et al. (2011), all of which lead to maintaining a proper
body weight.
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Previewsearly-onset obesity, and such
mutations are present in
0.5%–5% of severely obese
individuals (Farooqi et al.,
2003). Xu et al., through
conditional deletion of ERa in
POMC-expressing neurons,
determined that in female
mice, signaling through ERa
is important for the effects
these neurons have on food
intake.
This study represents the
first demonstration of a
tissue-specific suppression
of ERa leading to profound
effects on energy balance,
fat partitioning, andmetabolic
parameters. However, pe-
ripheral estrogen signaling—
through ERa in the liver, myo-
cytes, adipocytes, or other
tissues—may still be impor-
tant in modulating these
metabolic effects and needs
to be considered. In fact,
recently it was demonstrated
that tissue-specific deletion
of ERa in myeloid or hemato-
poietic cells led to increasedadipocyte mass coupled with glucose
intolerance and insulin resistance (Ribas
et al., 2011). In future studies of animals
with SF1- or POMC-specific ERa dele-
tions, a comparison group of animals
with whole-body ERa deletions would be
helpful in determining towhat extent these
conditional deletions recapitulate the
metabolic phenotype of animals with
a global whole-body deficiency.
While studies of the actions of ERa in
other tissues should continue, this does436 Cell Metabolism 14, October 5, 2011 ª20not discount the importance of the find-
ings in this study. Identification of specific
targets by which estrogen signaling
impacts food intake and energy expendi-
ture is an essential step toward the devel-
opment of targeted therapies. Further
investigation of the coactivators and
signaling mechanisms involved in ERa-
dependent activation of the SF1 and
POMC neurons should be undertaken
with the hopes of eventually developing
a pharmacologic treatment for the bur-11 Elsevier Inc.geoning obesity epidemic
and its comorbidities.
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